RT Journal Article
T1 Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients.
A1 Delgado-Ureña, Mayte
A1 Ortega, Francisco G
A1 de Miguel-Pérez, Diego
A1 Rodriguez-Martínez, Alba
A1 García-Puche, Jose L
A1 Ilyine, Hugh
A1 Lorente, Jose A
A1 Exposito-Hernandez, Jose
A1 Garrido-Navas, M Carmen
A1 Delgado-Ramirez, Miguel
A1 Serrano, M José
K1 Bevacizumab
K1 Circulating tumor cells
K1 CyCAR
K1 Metastatic colorectal cancer
K1 Prognosis
K1 RECIST
AB The use of circulating tumor cells (CTCs) as indicators of treatment response in metastatic colorectal cancer (mCRC) needs to be clarified. The objective of this study is to compare the Response Evaluation Criteria in Solid Tumors (RECIST) with the Cytologic Criteria Assessing Response (CyCAR), based on the presence and phenotypic characterization of CTCs, as indicators of FOLFOX-bevacizumab treatment response. 77 mCRC blood samples from FOLFOX-bevacizumab treated patients were analyzed to isolate CTCs before and after (12 and 24 weeks) treatment, using an immunomagnetic separation method. VEGFR expression was identified by double immunostaining. We observed a decrease of CTCs (42.8 vs. 18.2%) and VEGFR positivity (69.7% vs. 41.7%) after treatment. According to RECIST, 6.45% of the patients did not show any clinical benefit, whereas 93.55% patients showed a favorable response at 12 weeks. According to CyCAR, 29% had a non-favorable response and 71% patients did not. No significant differences were found between the response assessment by RECIST and CyCAR at 12 or 24 weeks. However, in the multivariate analysis, RECIST at 12 weeks and CyCAR at 24 weeks were independent prognostic factors for OS (HR: 0.1, 95% CI 0.02-0.58 and HR: 0.35, 95% CI 0.12-0.99 respectively). CyCAR results were comparable to RECIST in evaluating the response in mCRC and can be used as an alternative when the limitation of RECIST requires additional response analysis techniques.
YR 2018
FD 2018-09-06
LK http://hdl.handle.net/10668/12914
UL http://hdl.handle.net/10668/12914
LA en
DS RISalud
RD May 9, 2025